Tourmaline Bio, Inc. (TRML) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 47.98 |
| Open | 47.98 |
| Day High | 47.98 |
| Day Low | 47.98 |
| 52-Week High | 48.27 |
| 52-Week Low | 11.56 |
| Volume | 783,730 |
| Average Volume | 925,778 |
| Market Cap | 1.23B |
| PE | -13.95 |
| EPS | -3.44 |
| Moving Average 50 Days | 40.68 |
| Moving Average 200 Days | 22.74 |
| Change | 0 |
Data not available
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
GlobeNewswire Inc.
Sep 09, 2025 5:03 AM GMT
– Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion – – Transaction reflects the potential of Tourmaline’s pacibekitug, a long-acting, fully-human, anti-IL-6 monoclonal antibody wit
Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
GlobeNewswire Inc.
Aug 31, 2025 2:23 PM GMT
– Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across clinically-meaningful subgroups – – Pacibekitug demonstrated concordant, statistically significant reductions in secondary p
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
GlobeNewswire Inc.
May 19, 2025 8:05 PM GMT
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and